Drug interactions between exenatide and pegvisomant
Interactions between your drugs
Applies to: pegvisomant and exenatide
Pegvisomant may help control blood glucose levels in some patients, which may lead to a reduction in your dosage requirement of exenatide or any other diabetic medications you are receiving. Your blood glucose should be closely monitored so that medications may be adjusted accordingly by your doctor. Let your doctor know if you experience hypoglycemia, or low blood sugar. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Likewise, if pegvisomant is discontinued, your blood glucose may increase and hyperglycemia may occur, which may require readjustment of your medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: exenatide
You should take exenatide twice a day, at any time within the 60 minutes (1 hour) before your morning and evening meals, or before the two main meals of the day, and at least 6 hours or more apart. You may experience decreased absorption of exenatide in the presence of food or other medications. Your other medications should be administered at least 1 hour before or 2 hours after your exenatide injection.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|